MIMESIS

NEWSLETTER #3 / APRIL 2018

ENYO PHARMA

ENYO Pharma's MIMESIS drug discovery approach has already discovered new drug development starting points for RSV, ICD (Immunogenic Cell Death) and Zika.

With 3.6 million euros spending over 24 months, ENYO Pharma is optimizing at least five therapeutic starting points to modulate the function of novel human targets. This holds the promise of novel drug development for many indications with unmet need.

MIMESIS Timeline & Current Status



18 months after the start of MIMESIS Project, ENYO Pharma has achieved great first results:

For MIMESIS, a library of 10,000 small molecules was generated & screened, top priority hits have been validated and prioritized. ENYO Pharma has already selected several top priority hit chemical series to progress into hit-to-lead development:

Respiratory Syncitial Virus

A novel chemical series has been identified with anti-viral IC50 = 5 nM. Efforts are ongoing to confirm the mode of action and progress to in vivo proof of principle.

Induction of Immunogenic Cell Death

Two chemical series have been identified that induce the hallmarks of ICD in human and mouse tumor cells. The mode of action of one series has been confirmed and efforts are progressing to proof of principle in primary human DC/tumor cell phagocytosis assays.

Zika Virus

More than one chemical series has been identified with sub-uM anti-viral IC50. Further optimization of the scaffolds will identify the top priority Zika lead.

Partnerships

Partnership discussions have been initiated and ENYO Pharma will present output of the MIMESIS programme at four conferences during Q2 & 3 2018.

A new wave of molecule optimization will be initiated on HRV, Flu and TB during Q2 & Q3 2018.

Objectives for final phase of the MIMESIS project:

1. Continue to prioritize & derisk chemical series
2. Clearly define the mode of action of more than one priority scaffold
3. Successfully achieve disease proof of principle in rodents or primary human assay systems
4. Increase the number of partnering discussions to promptly identify partners attracted by an early stage relationship to co-develop lead series with best probability of success.

Conclusion

The MIMESIS library, inspired by viral strategies to modulate host cell biology, is a unique compound collection enriched with a higher than expected percentage of active molecules and succeeds in offering a pioneering and disruptive technology to identify new starting points for drug candidates in the fields of both infectious diseases and oncology. The approach is also applicable to a large number of pathologies with various etiologies since it targets cellular human pathways.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement n° 739086-MIMESIS.

Contact: Jacky Vonderscher, CEO / Eric Meldrum, CSO

mimesis@enyopharma.com

FOLLOW US ON: www.enyopharma.com